BioCentury
ARTICLE | Company News

FDA approves Jazz's Sunosi for daytime sleepiness

March 21, 2019 12:20 AM UTC

FDA approved late Wednesday Sunosi solriamfetol from Jazz to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea.

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) expects to launch Sunosi following a final scheduling decision by the U.S. Drug Enforcement Agency, which the company said is typically within 90 days of approval. Chairman and CEO Bruce Cozadd told BioCentury Sunosi's price will be disclosed at the time of launch...